CurrentUnitedHealthcarePolicy N/A

Medical Policy Update Bulletin Quick View : March 2026

A summary bulletin listing recently new, updated, revised, replaced, and retired UnitedHealthcare medical policies and medical benefit drug policies with effective dates for each change; serves as a pointer to full policy documents rather than a detailed coverage policy itself.

Policy Summary

PayerUnitedHealthcare

PolicyMedical Policy Update Bulletin Quick View : March 2026

Policy CodePolicy N/A

Change TypeMultiple (Updated/Revised)

Effective DateApr 1, 2026

Next Review Date

Key ActionProviders must consult the specific updated, revised, new, replaced, or retired Medical Policy or Medical Benefit Drug Policy for clinical coverage criteria, prior authorization requirements, and billing guidance; the bulletin itself does not establish coverage.

SourceLink

POLICY UPDATE CHANGES

Lower Extremity Endovascular Procedures policy status revised with an effective date of May 1, 2026.

Category III Codes policy status updated effective Apr. 1, 2026.

Embolization of the Ovarian and Iliac Veins for Pelvic Congestion Syndrome status updated effective Mar. 1, 2026.

Lower Extremity Endovascular Procedures status updated effective Mar. 1, 2026.

Preventive Care Services policy revised effective Apr. 1, 2026.

Spinal Fusion and Decompression policy revised effective Apr. 1, 2026.

Surgery of the Hip policy updated effective Mar. 1, 2026.

Surgery of the Knee policy updated effective Mar. 1, 2026.

Treatment of Temporomandibular Joint Disorders revised effective Mar. 1, 2026.

Vertebral Body Tethering for Scoliosis revised effective Apr. 1, 2026.

Complement C5 Inhibitors drug policy revised effective Apr. 1, 2026.

Denosumab drug policy revised effective Apr. 1, 2026.

Evkeeza (Evinacumab-Dgnb) drug policy updated effective Apr. 1, 2026.

FcRn Blockers drug policy revised effective Apr. 1, 2026.

Oncology Medication Clinical Coverage revised effective Apr. 1, 2026.

Ophthalmologic VEGF Inhibitors drug policy revised effective Apr. 1, 2026.

Provider Administered Drugs - Site of Care policy revised effective Apr. 1, 2026.

Respiratory Interleukins (Cinqair, Fasenra, & Nucala) updated effective Apr. 1, 2026.

Somatostatin Analogs drug policy revised effective Apr. 1, 2026.

Uplizna (Inebilizumab-Cdon) drug policy revised effective Apr. 1, 2026.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Summary of Policy Status Changes

This bulletin is an index of recent UnitedHealthcare and UMR medical policy status changes (new, updated, revised, replaced, retired) and serves as a pointer to the full policy documents listed below. It is intended to summarize policy status changes and effective dates but does not itself define coverage.

Providers should review the list of policy changes below and then consult the full policy documents at UHCprovider.com/policies for clinical criteria, prior authorization requirements, and billing rules; this bulletin only indexes policy status changes and is not a coverage determination.

Key dates & metadata

Effective dateApr 1, 2026

Most common drug update dateApr 1, 2026

Number of policies listed22

SubjectMedical Policy Update Bulletin Quick View - March 2026

Glossary: New — New: New clinical coverage criteria have been adopted for a health service.

Updated — Updated: An existing policy has been reviewed and clinical coverage criteria remain unchanged, but items like clinical evidence, FDA information, or code lists may have been updated.

Revised — Revised: An existing policy has been reviewed and clinical coverage criteria were changed.

Replaced — Replaced: An existing policy has been replaced with a new or different policy.

Retired — Retired: The health services are no longer being managed or are considered proven/medically necessary and are not excluded as unproven/not medically necessary unless documented elsewhere.

Policy status changes (new, updated, revised, replaced, retired)

Policy name	Change type	Effective date	Material change
Lower Extremity Endovascular Procedures	revised	May 1, 2026	true
Category III Codes	updated	Apr 1, 2026	false
Embolization of the Ovarian and Iliac Veins for Pelvic Congestion Syndrome	updated	Mar 1, 2026	false
Lower Extremity Endovascular Procedures	updated	Mar 1, 2026	false
Preventive Care Services	revised	Apr 1, 2026	true
Spinal Fusion and Decompression	revised	Apr 1, 2026	true
Surgery of the Hip	updated	Mar 1, 2026	false
Surgery of the Knee	updated	Mar 1, 2026	false
Treatment of Temporomandibular Joint Disorders	revised	Mar 1, 2026	true
Vertebral Body Tethering for Scoliosis	revised	Apr 1, 2026	true
Complement C5 Inhibitors	revised	Apr 1, 2026	true
Denosumab	revised	Apr 1, 2026	true
Evkeeza (Evinacumab-Dgnb)	updated	Apr 1, 2026	false
FcRn Blockers	revised	Apr 1, 2026	true
Oncology Medication Clinical Coverage	revised	Apr 1, 2026	true
Ophthalmologic VEGF Inhibitors	revised	Apr 1, 2026	true
Provider Administered Drugs - Site of Care	revised	Apr 1, 2026	true
Respiratory Interleukins (Cinqair, Fasenra, & Nucala)	updated	Apr 1, 2026	false
Somatostatin Analogs	revised	Apr 1, 2026	true
Uplizna (Inebilizumab-Cdon)	revised	Apr 1, 2026	true

Code-group highlights

Category III Codes (policy status updated)CPT

No codes listed

What providers must do

Documentation Required

Refer to individual policies for coverage determinations

Providers must consult the specific updated, revised, new, replaced, or retired Medical Policy or Medical Benefit Drug Policy for clinical coverage criteria, prior authorization requirements, and billing guidance; the bulletin itself does not establish coverage.

Documentation Required

Obtain member consent when service is not covered

Physicians and health care professionals may not bill members for services not covered by the member's benefit plan unless they first obtain the member's written consent acknowledging noncoverage and agreement to be billed directly.

For clinical criteria, prior authorization requirements, and billing guidance, providers must consult the full Medical Policies and Medical Benefit Drug Policies available at UHCprovider.com/policies under UnitedHealthcare | UMR Medical & Drug Policies; this bulletin only indexes changes and does not establish coverage.

FAQs & Definitions

Q: Does inclusion in this bulletin imply coverage? A: No; inclusion indicates adoption or change to a policy but does not imply that UnitedHealthcare provides coverage; coverage must be determined by the member's benefit plan and applicable law.

Q: Where are the full policy details? A: Full policies and detailed criteria are available at UHCprovider.com/policies under UnitedHealthcare | UMR Medical & Drug Policies.

Reminder: This bulletin is an index of policy status changes and serves as a pointer to full policy documents; it does not itself establish coverage.

Document changes

2026-05-01revisedLatest

Lower Extremity Endovascular Procedures policy status revised with an effective date of May 1, 2026. (Also listed as updated with effective date Mar. 1, 2026.)

2026-04-01updated

Category III Codes policy status updated effective Apr. 1, 2026.

2026-03-01updated

Embolization of the Ovarian and Iliac Veins for Pelvic Congestion Syndrome status updated effective Mar. 1, 2026.